Edition:
India

Amgen Announces Positive Top-Line Results From Otezla® Phase 3 Advance Study In Mild-To-Moderate Plaque Psoriasis


Wednesday, 6 May 2020 

May 6 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OTEZLA® (APREMILAST) PHASE 3 ADVANCE STUDY IN MILD-TO-MODERATE PLAQUE PSORIASIS.AMGEN INC - STUDY SHOWED THAT ORAL OTEZLA 30 MG TWICE DAILY ACHIEVED A STATISTICALLY SIGNIFICANT IMPROVEMENT, COMPARED WITH PLACEBO.AMGEN INC - ADVERSE EVENTS OBSERVED IN THIS TRIAL WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF OTEZLA.AMGEN INC - OTEZLA TREATMENT RESULTED IN SIGNIFICANT IMPROVEMENTS IN MEASURES OF MILD-TO-MODERATE PSORIASIS COMPARED WITH PLACEBO.